AK
Therapeutic Areas
Curasight Pipeline
| Drug | Indication | Phase |
|---|---|---|
| uTREAT® (177Lu-CUR-N86) | Glioblastoma (Recurrent) | Phase 1/2a |
| uTREAT® | Prostate Cancer | Preclinical |
| uTRACE® (68Ga-CUR-N86) | Diagnostic Imaging (Multiple Solid Tumors) | Phase 2 |
Leadership Team at Curasight
UK
Ulrich Krasilnikoff
Chief Executive Officer & Chief Financial Officer
HD
Hanne Damgaard Jensen
Chief Operating Officer
SF
Søren Fabricius
Chief Development Officer
KD
Kirsten Drejer
Chairperson of the Board
MR
Marcel Reichen
Board Member
DC
Dr. Colin Hayward
Board Member